A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in ...

Levacetylleucine (AQNEURSA) is approved for the treatment of ataxia in adults and pediatric patients with ataxia-telangiectasia weighing at least 15 kg, in addition to its existing indication for ...

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes] ...

"Unmet Needs and Mechanisms Behind Newer Agitation Therapies" takes up what still remains unmet in agitation care, and the biology behind a newer treatment option.

The 2026 AHA/ASA adult stroke rehabilitation guideline updates the 2016 framework, addressing evidence-based recovery ...

HIMALAYA was a multicenter, randomized, double-blind, placebo-controlled phase 2 trial conducted at 63 sites across 13 ...

Results recently published from the phase 2 HIMALAYA trial reported that SAR443820 did not slow functional decline, and was associated with more adverse events and treatment discontinuations in ...

The FDA has approved UX111 (Fayuvi; Ultragenyx Pharmaceutical), an adeno-associated virus serotype 9 (AAV9) gene therapy, for the treatment of pediatric patients with Sanfilippo syndrome type A ...

Foundational health behaviors reduce migraine burden, but frequent or disabling attacks commonly require preventive treatment ...

EPOCH is a single-center, prospective, randomized, open-label, blinded-endpoint (PROBE) trial being conducted at National Taiwan University Hospital. The study was registered in March 2024, and ...

In early September, the FDA approved zilganersen injection (Zanvastro; Ionis) for the treatment of Alexander disease in pediatric and adult patients, marking the first approved th ...

The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare ...